Login to Your Account

Seeing the Light, Investors Give PCI $14.1M for Amphinex Study

By Nuala Moran

Wednesday, June 16, 2010
LONDON – Armed with the results of a Phase I/II trial in which its light-mediated chemotherapy product induced complete regression in all evaluable tumors, PCI Biotech A/S has raised NOK90 million (US$14. 1 million) in an oversubscribed round to fund a Phase II/III registration trial in head and neck cancers. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription